Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 915 clinical trials
Featured trial
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old. One serious reaction complicating bone marrow transplants …

  • 569 views
  • 22 Dec, 2020
  • 1 location
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

myelodysplastic syndrome (mds)
aplastic anemia
anemia studies
anemia
myelodysplastic syndromes
  • 172 views
  • 22 Dec, 2020
  • 1 location
Featured trial
ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

  • 598 views
  • 08 Nov, 2020
  • 1 location
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) …

  • 0 views
  • 27 Jun, 2022
  • 5 locations
Azole-echinocandin Combination Therapy for Invasive Aspergillosis

The goals of this study are 3-fold: First, the main study and the primary endpoint will evaluate if the overall mortality can be decreased with initial azole-echinocandin combination therapy compared with triazole monotherapy in patients with IA and documented voriconazole susceptibility. Second, the study design described will also allow to …

  • 0 views
  • 16 Oct, 2021
  • 4 locations
Liver Cell Transplant for Phenylketonuria

Human phenylketonuria (PKU) results from phenylalanine hydroxylase (PAH) deficiency, and represents one of the most common and extensively studied single-gene Mendelian disorders in humans. Unfortunately, optimum clinical outcome demands lifelong dietary restriction through adherence to an unpalatable and expensive artificial diet. Challenges in maintaining traditional therapy lead to increasing phenylalanine …

phenylalanine
kuvan
deficiency
sapropterin
psychological assessment
  • 40 views
  • 22 Mar, 2022
  • 1 location
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

) followed by hematopoietic cell transplantation (HCT).

busulfan
melphalan
ejection fraction
cell transplantation
cyclophosphamide
  • 4 views
  • 30 Apr, 2022
  • 1 location
Muscle Stimulation for Physical Function During Stem Cell Transplant

Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to exposures including Agent Orange and an increased percentage of patients of African American ethnicity. Hematologic transplantation (HCT) is a common treatment for these cancers, but often …

  • 0 views
  • 14 May, 2022
  • 1 location
Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Caregivers

cancer treatment, hematopoietic cell transplantation (HCT), with multiple sequelae including graft-versus-host disease and cardiovascular and pulmonary complications. PA is diminished post-transplant

  • 0 views
  • 16 May, 2022
  • 1 location
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, …

  • 0 views
  • 24 Feb, 2022
  • 1 location